"Mind the Gap": an unmet need for new therapy in IBD.
Most physicians believe that the drugs they prescribe will work in their patients and thus have made little preparation for alternative strategies in the event of failure. In the treatment of inflammatory bowel disease (IBD), achieving a remission rate of 20% to 30% or a response rate of 50% to 60% is highly acceptable. This review focuses primarily on placebo-controlled trials that evaluated "usual" treatments for IBD in terms of induction and maintenance of remission, and identifies the "gaps" (ie, the percentage of patients lacking any benefit) in currently available treatments for IBD. Approximately, 40% to 60% of patients will not benefit from the available treatments, indicating a considerable unmet need for new, more effective therapies.
Katz
Seymour
S
Department of Medicine, New York University School of Medicine, New York, USA. SeymourKatz@optonline.net
D003093:Colitis, Ulcerative / Q000188:drug therapy; D018849:Controlled Clinical Trials as Topic; D003424:Crohn Disease / Q000188:drug therapy; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D012074:Remission Induction / Q000379:methods*; D055502:Secondary Prevention; D017211:Treatment Failure